MS200647-0005
08 Dec 2020
Trial Summary
The main purpose of this study is to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.
Acronym:
MS200647-0005
ACTRN/NCT /ethics:
NCT03840902
Scientific title:
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
Sponsor / Cooperative group:
EMD Serono Research & Development Institute
Trial & Patient Characteristics
| Cancer Type | Lung & mesothelioma |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | Non-small Cell Lung Cancer |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2019-04-16 |
| Anticipated End Date | 2028-01-26 |
Participating Hospitals
| Hospital | Calvary Central Districts Hospital |
|---|---|
| Clinical Trial Coordinator | Julie Rowe |
| julie.rowe@calvarycare.org.au | |
| Phone | 08 8239 9536 |
| Principal Investigator | Dr Rohit Joshi |
| Recruitment Status | Recruiting |